

Source	Country	Study design	Age at treatment	Study groups	Duration of follow-up	Parasitological endpoints	Serological endpoints <sup>1</sup>
<i>Aguiar et al., 2012</i> [33]	Brazil	Cohort	Adults	BNZ (n=29): 5 mg/kg/d for 60 days  Control (n=10): no treatment	1-29 y	HC, Nested PCR, XD	IIF <sup>2</sup> , ELISA <sup>2</sup>
<i>Britto et al., 2001</i> [58]	Brazil	Cohort	Children & adults	BNZ (n=26): 5-6 mg/kg/d for 30-60 days  NFTX (n=27): 7-8 mg/kg/d for 60-90 days  Placebo (n=15)	20 y (mean)	PCR, XD	Not reported
<i>Silveira et al., 2000</i> [62]			Children	BNZ (n=10): 5-7 mg/kg/d for 60 days  NFTX (n=2): 7-8 mg/kg/d for 60-90 days	8 & 20 y		ELISA, IHA, IIF
<i>Cancado et al., 1976</i> [72]	Brazil	Cohort	Children & adults	NFTX (n=15): 10 mg/kg/d for 60-120 days  Placebo (n=5)	2 y	XD	CF, HA, IF
<i>Cancado, 2002</i> [57]	Brazil	Cohort	Children & adults	BNZ (n=113): 5-10 mg/kg/d for 40 days	6-18 y	Not reported	CF, HA, IF, ELISA
<i>Cerisola et al., 1977</i> [71]	Argentina Brazil Chile	Cohort	Adults	NFTX (n=109): 8-10 mg/kg/d for 60-120 days  Control (n=30): no treatment	11 mo	XD	Not reported
<i>Coura et al., 1997</i> [26]	Brazil	RCT	Adults	BNZ (n=26): 5 mg/kg/d for 30 days  NFTX (n=27): 5 mg/kg/d for 30 days  Placebo (n=24)	12 mo	XD	CF, IF
<i>de Andrade et al., 1996</i> [27]	Brazil	RCT	Children	BNZ (n=64): 7.5 mg/kg/d for 60 days  Placebo (n=65)	3 y	Not reported	AT-ELISA <sup>3</sup> , ELISA, IHA, IIF
<i>Galvão et al., 2003</i> [24]				BNZ (n=58)		PCR	Not reported
<i>Andrade et al., 2004</i> [23]				Placebo (n=53)	6 y	Not reported	AT-ELISA <sup>3</sup>
<i>de Castro et al., 2006</i> [48]	Brazil	Cohort	Adults	BNZ (n=27): 5 mg/kg/d for 60 days  Control (n=13): no treatment	24 mo	HC	Not reported
<i>de Lana et al., 2009</i> [40]	Brazil	Cohort	Children & adults	BNZ (n=28): 5-10 mg/kg/d for 40-60 days	9 y	HC, PCR	ELISA, FC-ALTA-IgG ELISA <sup>3</sup>
<i>Machado-de-Assis et al., 2013</i> [30]					13 y		ELISA <sup>2</sup> , IHA <sup>2</sup>

<i>de Oliveira, 1990</i> [68]	Brazil	Cohort	Children & adults	BNZ (n=50): 5-8 mg/kg/d for 60 days  NFTX (n=50): 10-15 mg/kg/d for 60-120 days	5 to 18 y	XD	CF, IF, HA	
<i>Diniz-Marques et al., 2003</i> [56]	Brazil	Cohort	Children	BNZ (n=48): 5-10 mg/kg/d for 60 days	24 mo	Not reported	ELISA, IHA, IIF	
<i>Escribà et al., 2009</i> [41]	Honduras	Cohort	Children	BNZ (n=2,275): 5-7.5 mg/kg/d for 60days	18-36 mo	Not reported	ELISA <sup>2</sup>	
<i>Yun et al., 2009</i> [45]	Bolivia Guatemala				18-60 mo & 36 mo			
<i>Fabbro et al., 2000</i> [60]	Argentina	Cohort	Children & adults	BNZ (n=36): 5 mg/kg/d for 30 days  NFTX (n=32): 5-8 mg/kg/d for 60 days  Control (n=130): no treatment	14 y (mean)	XD	DA-2ME, IHA, IIF	
<i>Fabbro et al., 2007</i> [47]			Adults	BNZ (n=27)  NFTX (n=27): 8-10 mg/kg/d for 45-60 days  Control (n=57)	21 y (mean)		DA-2ME, ELISA <sup>2</sup> , IHA, IIF	
<i>Fabbro et al., 2010</i> [37]								
<i>Fabbro et al., 2013</i> [28]						BNZ (n=13) NFTX (n=16) Control (n=37)	23 y (mean)	Not reported
<i>Fernandes et al., 2009</i> [42]	Brazil	Cohort	Children & adults	BNZ (n=80): 5 mg/kg/d for 60 days  Control (n=50): no Chagas disease	36 mo	HC, PCR	ELISA <sup>2</sup> , IIF <sup>2</sup>	
<i>Flores-Chavez et al., 2006</i> [49]	Bolivia	Cohort	Children	BNZ (n=35): 8 mg/kg/d for 60 days	12 mo	PCR, XD	ELISA, ELISA for SAPA <sup>3</sup>	
<i>Galvão et al., 1993</i> [67]	Brazil	Cohort	Adults	BNZ: 8-10 mg/kg/d for 30-60 days & NFTX: 5-7 mg/kg/d for 30-60 days (n=85)  Control (n=101): no treatment	3-10 y	HC	CF, CoML, IIF	
<i>Gallerano et al., 2000</i> [61]	Argentina	Cohort	Adults	BNZ (n=130): 4-8 mg/kg/d for 45-60 days  NFTX (n=96): 10 mg/kg/d for 45-60 days  Control (n=668): no treatment	5,3 y	XD	IHA, IIF	
<i>Hasslocher-Moreno, 2010</i> [38]	Brazil	Cohort	Adults	BNZ (n=62): 5 mg/kg/for 30-60 days  Control (n=62): no treatment	140,9 mo (± 47.8)	XD	IIF <sup>2</sup>	
<i>Jackson et al., 2013</i> [29]	Switzerland	Cohort	Adults	NFTX (n=37): 10 mg/kg/d for 30-60 days	3 y	PCR	ELISA	

<i>Lacunza et al., 2006</i> [50]	Argentina	Cohort	Adults	BNZ (n=14): 5 mg/kg/d for 60 days  Control (n=5): no treatment	6 mo	PCR	ELISA <sup>2</sup> , IHA <sup>2</sup>
<i>Levi et al., 1971</i> [74]	Brazil	Cohort	Adults	NFTX (n=12): 5-17 mg/kg/d for 120 days	3 y	Not reported	CF
<i>Machado-de-Assis et al., 2012</i> [34]	Brazil	Cohort	Children & adults	BNZ (n=94): 5 mg/kg/d for 60 days	16.9 y (± 6.8)	HC, PCR	ELISA <sup>2</sup> , IHA <sup>2</sup> , IIF <sup>2</sup> , TESA-blot
<i>Maekelt, 1969</i> [75]	Venezuela	Cohort	Adults	NFTX (n=14): 5-15 mg/kg/d for 120 days	10 mo	Not reported	CF, IHA
<i>Maldonado et al., 1995</i> [65]	Paraguay	Cohort	Children	BNZ (n=20): 5-7 mg/kg/d for 60 days	6 mo	HC, PCR, XD	ELISA, IIF
<i>Vera de Bilbao et al., 2004</i> [54]				BNZ (n=12)	24 mo	XD	
<i>Meira et al., 2004</i> [53]	Brazil	Cohort	Adults	BNZ (n=31): 5 mg/kg/d for 60 days	27.7 mo (mean)	HC, PCR	CoML, ELISA, IHA, IIF, rCRP ELISA <sup>3</sup>
<i>Molina et al., 2014</i> [22]	Spain	RCT	Adults	BNZ (n=26): 150 mg twice daily for 60 days	10 mo	rt-PCR	ELISA <sup>2</sup>
<i>Moretti et al., 1998</i> [63]	Argentina	Cohort	Children & adults	BNZ & NFTX (n=42). No further details were provided.  Control (n=42): no treatment	2-20 y	Not reported	HA, IF, ELISA <sup>3</sup>
<i>Muñoz et al., 2013</i> [31]	Chile	Cohort	Adults	NFTX (n=21): 6 mg/kg/d for 60 days	13 mo	rt-PCR, XD	Not reported
<i>Murcia et al., 2010</i> [39]	Spain	Cohort	Children & adults	BNZ (n=181): 5-7 mg/kg/d for 60 days	35 mo	PCR	IIF <sup>2</sup>
<i>Neves da silva et al., 1974</i> [73]	Brazil	Cohort	Adults	NFTX (n=15): 8-10 mg/kg/d for 120 days  Placebo (n=10)	48 mo	XD	HA, IF
<i>Pérez Ayala et al., 2011</i> [35]	Spain	Cohort	Adults	BNZ (n=64): 5 mg/kg/d for 30-60 days	1 y (mean)	PCR	ELISA, IHA
<i>Rumi et al., 2013</i> [32]	Argentina	Cohort	Children	BNZ (n=221): 5 mg/kg/d for 60 days	2-5 y	PCR	ELISA <sup>2</sup> , IHA <sup>2</sup>
<i>Sánchez Negrette et al., 2008</i> [46]	Argentina	Cohort	Adults	BNZ (n=18): 5 mg/kg/d for 60 days	24-66 mo	Not reported	CMA-ELISA <sup>2</sup> , IRA-ELISA & RAM-ELISA <sup>2,3</sup> , IHA <sup>2</sup>
<i>Shenone et al., 1981</i> [70]	Chile	Cohort	Adults	BNZ (n=6): 8-15 mg/kg/d for 30 days  NFTX (n=15): 5-15 mg/kg/d for 60-120 days  Placebo (n=8) for 120 days	83 mo (mean)	XD	Not reported
<i>Solari et al., 1998</i> [64]	Chile	Cohort	Children	NFTX (n=28): 7 mg/kg/d for 60 days	6 mo	PCR, XD	Not reported
<i>Solari et al., 2001</i> [59]				NFTX (n=66)	3 y		ELISA, HAI

<i>Streiger et al., 2004</i> [55]	Argentina	Cohort	Children	BNZ (n=64): 5 mg/kg/for 30 days  NFTX (n=7): 12-15 mg/kg/d for 45-60 days  Control (n=24): no treatment	12 y (median)	Not reported	DA-2ME, ELISA <sup>2</sup> , IHA, IIF
<i>Sosa-Estani et al., 1998</i> [25]	Argentina	RCT	Children	BNZ (n=55): 5 mg/kg/d for 60 days  Placebo (n=51)	4 y	XD	ELISA, ELISA F29 <sup>3</sup> , IHA, IIF
<i>Sosa-Estani et al., 2009</i> [43]		Cohort	Adults	BNZ (n=16)	14 y	PCR, XD	
<i>Vera de Bilbao et al., 2006</i> [51]	Paraguay	Cohort	Children	BNZ (n=5): 5-7 mg/kg/d for 60 days	10 y	Micromethod	ELISA, IIF
<i>Vigliano et al., 1989</i> [69]	Argentina	Cohort	Adults	BNZ (n=131): 5 mg/kg/d for 35 days  Control (n=70): no treatment	7.5 y (mean)	Not reported	CF, IHA, IIF
<i>Viotti et al., 1994</i> [66]	Argentina	Cohort	Adults	BNZ (n=131): 5 mg/kg/d for 30 days  Control (n=70): no treatment	8 y (mean)	XD	CF, IHA, IF
<i>Viotti et al., 2006</i> [52]	Argentina	Cohort	Adults	BNZ (n=283): 5 mg/kg/d for 30 days  Control (n=283): no treatment	9.8 y (mean)	Not reported	CF, IHA, IIF
<i>Viotti et al., 2009</i> [44]	Argentina	Cohort	Adults	BNZ (n=760): 5 mg/kg/d for 30 days  Control (n=1.075): no treatment	10.4 y ( $\pm 7.8$ )	Not reported	ELISA, IHA or IIF
<i>Viotti et al., 2011</i> [36]	Argentina	Cohort	Adults	BNZ (n=53): 5 mg/kg/d for 30 days  Control (n=89): no treatment	36 mo (mean)	Not reported	ELISA, IHA,IIF, multiplex serologic assay <sup>3</sup>